S
SXTPW
Materials60 Degrees Pharmaceuticals, Inc. Warrant
—
+0.00%
Live · NASDAQ · Mar 28, 6:08 AM
AI InsightNo insight available
What's Moving SXTPW Today?
No AI insight has been generated for SXTPW yet. Check back soon — insights are generated from recent news analysis.
Generated Insights
No insights have been generated for SXTPW yet. Check back soon.
SXTPW News
20 articles- 60 Degrees Pharmaceuticals Files New Dietary Ingredient Notification (NDIN) with FDA for Australian Chestnut ExtractYahoo Finance·Mar 18, 2026
- 60 Degrees Pharmaceuticals (SXTP) Partners With GoodRx to Expand Access to ARAKODAYahoo Finance·Feb 24, 2026
- 60 Degrees Pharmaceuticals Announces Third Quarter 2025 ResultsYahoo Finance·Nov 13, 2025
- 60 Degrees Pharmaceuticals and NDT Pharmaceuticals Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TVYahoo Finance·Oct 31, 2025
- 60 Degrees Pharmaceuticals Announces No Detection of Babesia Infection in First Patient Following Treatment with Tafenoquine in Relapsing Babesiosis StudyYahoo Finance·Oct 15, 2025
- 60 Degrees Pharmaceuticals Unveils Name of Chronic Babesiosis Clinical Trial: B-FREE Chronic Babesiosis StudyYahoo Finance·Oct 9, 2025
- Join 60 Degrees Pharmaceuticals' Exclusive Live Investor Webinar and Q&A Session on October 22Yahoo Finance·Oct 2, 2025
- Enlivex Therapeutics and 60 Degrees Pharmaceuticals Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TVYahoo Finance·Sep 19, 2025
- 60 Degrees Pharmaceuticals Live Webcast Link and New Date for Presentation at H.C. Wainwright 27th Annual Global Investment ConferenceYahoo Finance·Sep 3, 2025
- 60 Degrees Pharmaceuticals to Present at H.C. Wainwright 27th Annual Global Investment ConferenceYahoo Finance·Aug 21, 2025
- 60 Degrees to commence Phase II babesiosis trial at Mount SinaiClinicaltrialsarena·Aug 20, 2025
- 60 Degrees Pharmaceuticals Selects Icahn School of Medicine at Mount Sinai as Central Clinical Trial Site for Phase II Study to Evaluate Tafenoquine for Chronic BabesiosisYahoo Finance·Aug 19, 2025
- 60 Degrees Pharmaceuticals Second Quarter 2025 Earnings: Revenues DisappointYahoo Finance·Aug 18, 2025
- 60 Degrees Pharmaceuticals Announces Second Quarter 2025 ResultsYahoo Finance·Aug 13, 2025
- Aptevo Therapeutics and 60 Degrees Pharmaceuticals Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TVYahoo Finance·Aug 8, 2025
- 60 Degrees Pharmaceuticals and Tulane University Sign Research Agreement to Study Tafenoquine Against Lyme and Bartonella BacteriaYahoo Finance·Jul 17, 2025
- 60 Degrees Pharmaceuticals Announces Closing of up to $10 Million Public OfferingYahoo Finance·Jul 16, 2025
- 60 Degrees Pharmaceuticals Announces Pricing of Up to $10 Million Public OfferingYahoo Finance·Jul 15, 2025
- 60 Degrees Pharmaceuticals Defines Potential Human Babesiosis Market Size for ARAKODA® (tafenoquine): Annual Max TAM, Sales of $245 Million; Cumulative through Patent Expiration, $1.1 BillionYahoo Finance·Jul 15, 2025
- 60 Degrees Pharmaceuticals to Submit MUMS (Minor Use/Minor Species) Designation Request to FDA for Tafenoquine for Acute Canine Babesiosis in 2025Yahoo Finance·Jul 14, 2025
All 20 articles loaded
Price Data
Open—
Previous Close—
Day High—
Day Low—
52 Week High$0.16
52 Week Low$0.02
Fundamentals
Market Cap—
P/E Ratio—
EPS$-18.55
Dividend Yield—
Dividend / Share—
ROE-201.2%
Profit Margin-1,309.4%
Debt / Equity0.46
Trading
Volume—
Avg Volume (10D)8K
Shares Outstanding—
About 60 Degrees Pharmaceuticals, Inc. Warrant
60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The firm's pipeline products under development cover development programs for COVID-19, fungal, tick-borne, and other viral diseases.
1025 CONNECTICUT AVENUE NW, WASHINGTON, DC, 20036
3 employees
Listed July 12, 2023
MaterialsPHARMACEUTICAL PREPARATIONS
Company Details
Security TypeWarrant
ExchangeNASDAQ
CurrencyUSD
Round Lot100
SIC2834 — PHARMACEUTICAL PREPARATIONS
CIK0001946563
Composite FIGIBBG01H0F52W2
Share Class FIGI—